CC chemokine receptor 3 (CCR3), also known as CD193, belongs to class A of G protein-coupled receptors and is present in high levels in eosinophils, basophils, and airway epithelial cells. CCR3 is considered the therapeutic target for human immunodeficiency virus (HIV) infections and allergic diseases; therefore, the development of sensitive monoclonal antibodies (mAbs) for CCR3 has been desired. This study aimed to establish a specific and sensitive mAb against mouse CCR3 (mCCR3) useful for flow cytometry analysis by employing the Cell-Based Immunization and Screening (CBIS) method. The generated anti-mCCR3 mAb, C3Mab-2 (rat IgG2b, kappa), was found to react with mCCR3-overexpressed Chinese hamster ovary-K1 (CHO/mCCR3) cells, according to flow cytometric analysis. Also, it reacted with P388 (mouse lymphoid neoplasm) or J774-1 (mouse macrophage-like) cells, which express endogenous mCCR3. Taken together, C3Mab-2, generated by the CBIS method, can be a valuable tool for detecting mCCR3 on the surface of mouse cells.
Get full access to this article
View all access options for this article.
References
1.
ZlotnikA, and YoshieO: Chemokines: A new classification system and their role in immunity. Immunity, 2000; 12:121–127.
2.
GerardC, and RollinsBJ: Chemokines and disease. Nat Immunol, 2001; 2:108–115.
3.
Ben-BaruchA: Organ selectivity in metastasis: Regulation by chemokines and their receptors. Clin Exp Metastasis, 2008; 25:345–356.
4.
MurphyPM, BaggioliniM, CharoIF, HébertCA, HorukR, MatsushimaK, MillerLH, OppenheimJJ, and PowerCA: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev, 2000; 52:145–176.
5.
PostTW, BozicCR, RothenbergME, LusterAD, GerardN, and GerardC: Molecular characterization of two murine eosinophil beta chemokine receptors. J Immunol, 1995; 155:5299–5305.
6.
CombadiereC, AhujaSK, and MurphyPM: Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem, 1995; 270:16491–16494.
7.
WillemsLI, and IjzermanAP: Small molecule antagonists for chemokine CCR3 receptors. Med Res Rev, 2010; 30:778–817.
8.
StellatoC, BrummetME, PlittJR, ShahabuddinS, BaroodyFM, LiuMC, PonathPD, and BeckLA: Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells. J Immunol, 2001; 166:1457–1461.
9.
HeJ, ChenY, FarzanM, ChoeH, OhagenA, GartnerS, BusciglioJ, YangX, HofmannW, NewmanW, MackayCR, SodroskiJ, and GabuzdaD: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature, 1997; 385:645–649.
10.
KuseY, TsurumaK, KannoY, ShimazawaM, and HaraH: CCR3 is associated with the death of a photoreceptor cell-line induced by light exposure. Front Pharmacol, 2017; 8:207.
11.
DoranzBJ, RuckerJ, YiY, SmythRJ, SamsonM, PeiperSC, ParmentierM, CollmanRG, and DomsRW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell, 1996; 85:1149–1158.
12.
ChoeH, FarzanM, SunY, SullivanN, RollinsB, PonathPD, WuL, MackayCR, LaRosaG, NewmanW, GerardN, GerardC, and SodroskiJ: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 1996; 85:1135–1148.
FukudaK, KuoCH, MorohoshiK, LiuFT, and OnoSJ: The murine CCR3 receptor regulates both eosinophilia and hyperresponsiveness in IgE-mediated allergic conjunctivitis. Br J Ophthalmol, 2012; 96:1132–1136.
15.
ElsnerJ, EscherSE, and ForssmannU: Chemokine receptor antagonists: A novel therapeutic approach in allergic diseases. Allergy, 2004; 59:1243–1258.
16.
SongDJ, ShimMH, LeeN, YooY, and ChoungJT: CCR3 monoclonal antibody inhibits eosinophilic inflammation and mucosal injury in a mouse model of eosinophilic gastroenteritis. Allergy Asthma Immunol Res, 2017; 9:360–367.
17.
YamadaS, ItaiS, NakamuraT, YanakaM, SaidohN, ChangYW, HandaS, HaradaH, KagawaY, IchiiO, KonnaiS, KanekoMK, and KatoY: PMab-52: Specific and sensitive monoclonal antibody against cat podoplanin for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:224–230.
18.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
19.
GreenbaumJA, AndersenPH, BlytheM, BuiHH, CachauRE, CroweJ, DaviesM, KolaskarAS, LundO, MorrisonS, MumeyB, OfranY, PellequerJL, PinillaC, PonomarenkoJV, RaghavaGP, van RegenmortelMH, RoggenEL, SetteA, SchlessingerA, SollnerJ, ZandM, and PetersB: Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit, 2007; 20:75–82.
20.
FurusawaY, YamadaS, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. Biochem Biophys Rep, 2019; 18:100616.
21.
FurusawaY, KanekoMK, NakamuraT, ItaiS, FukuiM, HaradaH, YamadaS, and KatoY: Establishment of a monoclonal antibody PMab-231 for tiger podoplanin. Monoclon Antib Immunodiagn Immunother, 2019; 38:89–95.
22.
FurusawaY, TakeiJ, SayamaY, YamadaS, KanekoMK, and KatoY: Development of an anti-bear podoplanin monoclonal antibody PMab-247 for immunohistochemical analysis. Biochem Biophys Rep, 2019; 18:100644.
23.
FurusawaY, YamadaS, ItaiS, NakamuraT, TakeiJ, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin. Biochem Biophys Rep, 2019; 18:100631.
24.
FurusawaY, KanekoMK, and KatoY: Establishment of C(20)Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells. Oncol Lett, 2020; 20:1961–1967.
25.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C(44)Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
26.
SayamaY, KanekoMK, and KatoY: Development and characterization of TrMab-6, a novel anti-TROP2 monoclonal antibody for antigen detection in breast cancer. Mol Med Rep, 2021; 23:1.
27.
GrimaldiJC, YuNX, GrunigG, SeymourBW, CottrezF, RobinsonDS, HoskenN, FerlinWG, WuX, SotoH, O'GarraA, HowardMC, and CoffmanRL: Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol, 1999; 65:846–853.
28.
LevyJA: HIV pathogenesis: 25 years of progress and persistent challenges. AIDS, 2009; 23:147–160.
29.
TrkolaA, DragicT, ArthosJ, BinleyJM, OlsonWC, AllawayGP, Cheng-MayerC, RobinsonJ, MaddonPJ, and MooreJP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature, 1996; 384:184–187.
30.
MondorI, MoulardM, UgoliniS, KlassePJ, HoxieJ, AmaraA, DelaunayT, WyattR, SodroskiJ, and SattentauQJ: Interactions among HIV gp120, CD4, and CXCR4: Dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology, 1998; 248:394–405.
31.
IshiiT, IshidaT, UtsunomiyaA, InagakiA, YanoH, KomatsuH, IidaS, ImadaK, UchiyamaT, AkinagaS, ShitaraK, and UedaR: Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res, 2010; 16:1520–1531.
32.
RemerM, Al-ShamkhaniA, GlennieM, and JohnsonP: Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy, 2014; 6:1187–1206.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
